These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 9892879

  • 1. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
    Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ.
    Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
    [Abstract] [Full Text] [Related]

  • 2. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
    Delchier JC, Cohen G, Humphries TJ.
    Scand J Gastroenterol; 2000 Dec; 35(12):1245-50. PubMed ID: 11199361
    [Abstract] [Full Text] [Related]

  • 3. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Bianchi Porro G, Italian Rabeprazole Study Group.
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [Abstract] [Full Text] [Related]

  • 4. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study.
    Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ.
    Aliment Pharmacol Ther; 1999 Feb; 13(2):179-86. PubMed ID: 10102948
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
    Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL.
    Aliment Pharmacol Ther; 2002 Mar; 16(3):479-85. PubMed ID: 11876701
    [Abstract] [Full Text] [Related]

  • 6. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group.
    Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ.
    Dig Dis Sci; 2000 May; 45(5):845-53. PubMed ID: 10795744
    [Abstract] [Full Text] [Related]

  • 7. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
    Caos A, Breiter J, Perdomo C, Barth J.
    Aliment Pharmacol Ther; 2005 Aug 01; 22(3):193-202. PubMed ID: 16091056
    [Abstract] [Full Text] [Related]

  • 8. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD, Markham A.
    Drugs; 1999 Oct 01; 58(4):725-42. PubMed ID: 10551440
    [Abstract] [Full Text] [Related]

  • 9. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators.
    Aliment Pharmacol Ther; 2002 Mar 01; 16(3):445-54. PubMed ID: 11876697
    [Abstract] [Full Text] [Related]

  • 10. Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
    Galmiche JP, Zerbib F, Ducrottè P, Fournet J, Rampal P, Avasthy N, Humphries TJ.
    Aliment Pharmacol Ther; 2001 Sep 01; 15(9):1343-50. PubMed ID: 11552904
    [Abstract] [Full Text] [Related]

  • 11. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group.
    Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ.
    Aliment Pharmacol Ther; 1998 Aug 01; 12(8):789-95. PubMed ID: 9726393
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years.
    Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, Morocutti A, Miller N, Bardhan KD, European Rabeprazole Study Group.
    Aliment Pharmacol Ther; 2003 Feb 01; 17(3):343-51. PubMed ID: 12562446
    [Abstract] [Full Text] [Related]

  • 13. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ, Salas M, Ward A.
    Clin Ther; 2001 Jul 01; 23(7):998-1017. PubMed ID: 11519776
    [Abstract] [Full Text] [Related]

  • 14. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
    Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B, European Rabeprazole Study Group.
    Eur J Gastroenterol Hepatol; 2005 May 01; 17(5):559-66. PubMed ID: 15827447
    [Abstract] [Full Text] [Related]

  • 15. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI, Goa KL.
    Drugs; 2001 May 01; 61(15):2327-56. PubMed ID: 11772142
    [Abstract] [Full Text] [Related]

  • 16. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    Farley A, Wruble LD, Humphries TJ.
    Am J Gastroenterol; 2000 Aug 01; 95(8):1894-9. PubMed ID: 10950032
    [Abstract] [Full Text] [Related]

  • 17. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ, Boer WA, Geldof H, Hazelhoff B, Bergmans P, Tytgat GN, Smout AJ.
    Aliment Pharmacol Ther; 2004 Aug 15; 20(4):451-8. PubMed ID: 15298640
    [Abstract] [Full Text] [Related]

  • 18. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
    Archimandritis AJ, Nikolopoulou V, Kouklakis G, Paraskevas E, Avgerinos A, Tsianos E, Triantafillidis JK, Hellenic Rabeprazole Study Group.
    Curr Med Res Opin; 2005 Apr 15; 21(4):603-10. PubMed ID: 15899110
    [Abstract] [Full Text] [Related]

  • 19. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.
    Cloud ML, Enas N, Humphries TJ, Bassion S.
    Dig Dis Sci; 1998 May 15; 43(5):993-1000. PubMed ID: 9590413
    [Abstract] [Full Text] [Related]

  • 20. Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study.
    Kovacs TO, Wilcox CM, DeVault K, Miska D, Bochenek W, Pantoprozole US Gerd Study Group B.
    Aliment Pharmacol Ther; 2002 Dec 15; 16(12):2043-52. PubMed ID: 12452936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.